Loading
Life sciences · Journal article
Frontiers in Behavioral Neuroscience · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Post-traumatic stress disorder (PTSD) is increasingly recognized as a systemic disorder closely linked to metabolic dysfunction, including obesity, insulin resistance, type 2 diabetes and cardiovascular disease. These comorbidities are associated with poorer treatment response, yet pharmacological options for PTSD remain limited. Here, we review evidence that PTSD and metabolic disease share convergent mechanisms, including dysregulation of the hypothalamic–pituitary–adrenal axis, glucocorticoid receptor signaling, neuroinflammation, insulin resistance and mitochondrial dysfunction. We evaluate the rationale for repurposing approved cardiometabolic drugs, including glucagon-like peptide-1 receptor agonists, insulin sensitizers, statins, renin–angiotensin system modulators and glial-targeting agents. We critically assess preclinical and clinical evidence, highlight current limitations and propose a biomarker-guided framework to match therapies to dominant biological mechanisms. Finally, we discuss the exceptional burden of PTSD with cardiometabolic disease in war-affected Ukraine as a priority setting for future mechanism-based clinical trials. Drug repurposing represents a promising, but unproven, precision-psychiatry strategy.